Indaptus Therapeutics, Inc. 8-K/A

What Happened Indaptus Therapeutics, Inc. announced on April 17, 2026 (effective April 22, 2026) that the Board appointed Tim Ruan and Dr. Johnny Fox Arrowsmith (Yi Zhang) as independent directors. The appointments are effective April 22, 2026; both were named Class II directors with terms expiring at the Company’s 2026 annual meeting of stockholders. On April 22, 2026, director Matthew McMurdo resigned; the filing states his resignation was not due to any disagreement with the Company’s operations, policies, or practices.

Key Details

• Appointments effective April 22, 2026: Tim Ruan (age 40) and Dr. Johnny Fox Arrowsmith (age 48).
• Director roles and backgrounds: Ruan is currently CFO of Ocumension Therapeutics with prior senior roles at Goldman Sachs and Morgan Stanley; Dr. Arrowsmith is a partner at JunHe and a registered U.S. patent attorney with a Ph.D. and a J.D.
• Committee assignments: Ruan was named to the Audit Committee and is designated an "audit committee financial expert"; Dr. Arrowsmith was named to the Nominating Committee.
• Compensation and protections: Each new independent director will receive an annual cash retainer of $30,000 (payable quarterly) and will be covered by an indemnification agreement to the fullest extent permitted by Delaware law.

Why It Matters These filings document changes to Indaptus’s board composition and committee memberships — facts investors can use to assess the company’s governance and oversight structure. The addition of an audit committee financial expert (Tim Ruan) and an IP- and life-sciences-focused attorney (Dr. Arrowsmith) are specific, disclosed changes to the Board’s experience mix. The filing also discloses director compensation (annual $30,000 retainer) and indemnification arrangements, and confirms the departing director’s resignation was not due to a dispute with the company.